Nix G A, Dubbelman C, Wilson J H, Schütte H E, Jeekel J, Postema R R
Department of Radiology, University Hospital Dijkzigt Rotterdam, The Netherlands.
Cancer. 1991 Jan 15;67(2):529-35. doi: 10.1002/1097-0142(19910115)67:2<529::aid-cncr2820670235>3.0.co;2-3.
Two hundred twenty patients with a carcinoma in the head of the pancreas were divided into three tumor diameter groups: group 1, 0.5 to 4.4 cm (n = 72); group 2, 4.5 to 6.0 cm (n = 77); and group 3, 6.1 to 15.0 cm (n = 71). For these tumor diameter groups a six-fold eliminatory curability analysis was performed. Of the patients with liver metastases in group 1 the last patient had died at 10 months and in groups 2 and 3 no patients were alive at 18 months after the start of complaints. Patients with extrahepatic metastases did not survive 12 months in group 1, 16 months in group 2, and 25 months in group 3. The 6% actuarial survival rate for inoperable patients was reached in group 1 after 17 months, in group 2 after 36 months, and in group 3 after 27 months after the start of complaints. For groups 1 through 3 in curable, but not curatively operated patients, the respective 0% actuarial survival rate was reached at 24 months, 23 months, and 14 months. The 0% actuarial survival rate in patients with irresectable vessel invasion was reached in group 1 at 33 months, in group 2 at 23 months, and in group 3 at 25 months. The 0% actuarial survival rate in patients with an irresectable tumor was reached at 33 months, 31 months, and 27 months after the start of complaints in groups 1, 2, and 3, respectively. The 0% actuarial survival rate in curatively operated patients was reached in group 3 after 26 months and in group 2 after 29 months. In group 1 25% of the patients were alive at 36 months after the start of complaints. Small tumors were associated with the greatest chance of curative operation and on average had the longest survival. However, small tumors with liver or other metastases carried a worse prognosis than large tumors with liver or other metastases. If tumors were found not to be resectable at the time of operation, the size of the tumor did not appear to affect survival.
220例胰头癌患者被分为三个肿瘤直径组:第1组,0.5至4.4厘米(n = 72);第2组,4.5至6.0厘米(n = 77);第3组,6.1至15.0厘米(n = 71)。针对这些肿瘤直径组进行了六倍消除性可治愈性分析。在第1组有肝转移的患者中,最后一名患者在10个月时死亡,在第2组和第3组,自出现症状开始18个月后无患者存活。第1组有肝外转移的患者存活时间不超过12个月,第2组不超过16个月,第3组不超过25个月。不可手术患者的6%精算生存率在第1组于出现症状开始17个月后达到,第2组在36个月后达到,第3组在27个月后达到。对于第1至3组中可治愈但未接受根治性手术的患者,分别在24个月、23个月和14个月时达到各自的0%精算生存率。第1组在33个月时、第2组在23个月时、第3组在25个月时达到有不可切除血管侵犯患者的0%精算生存率。第1组、第2组和第3组分别在出现症状开始33个月、31个月和27个月时达到有不可切除肿瘤患者的0%精算生存率。第3组在26个月后、第2组在29个月后达到接受根治性手术患者的0%精算生存率。在第1组,25%的患者在出现症状开始36个月后仍存活。小肿瘤与根治性手术的最大机会相关,且平均存活时间最长。然而,有肝或其他转移的小肿瘤的预后比有肝或其他转移的大肿瘤更差。如果在手术时发现肿瘤不可切除,肿瘤大小似乎不影响生存。